1st May 2026 01:24
AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Says the US Food & Drug Administration's Oncologic Drugs Advisory Committee recommended the benefit–risk profile of Truqap when used with abiraterone and hormone‑lowering therapy for PTen‑deficient metastatic hormone‑sensitive prostate cancer. AstraZeneca says the recommendation follows late‑stage trial results showing the combination helps delay disease progression. The company adds it is the first targeted treatment to show benefit in this form of the disease and notes the decision follows the FDA's earlier acceptance of its application. Truqap is a targeted treatment designed to block a growth pathway used by cancer cells. Read More
